0
0 (0%)
Biostage, Inc. [HRGN]
Source:
Company Overview
Harvard Apparatus Regenerative Technology, Inc. is a clinical-stage biotechnology company focused on the development of regenerative medicine treatments for disorders of the gastro-intestinal system and other organs that result from cancer, trauma or birth defects.
| Country | United States |
| Headquarters | holliston, massachusetts |
| Phone Number | (774) 233-7300 |
| Industry | manufacturing |
| CEO | Junli He |
| Website | www.hregen.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0.4 |
| Operating Profit | $-7.7 |
| Net Income | $-7.7 |
| Net Cash | $2.1 |
Profit Ratios
| Gross Margin | $0.2 |
| Operating Margin | -1,796.7 |
| Profit as % of Revenues | -2.1% |
| Profit as % of Assets | -219.2% |
| Profit as % of Stockholder Equity | -240% |
Management Effectiveness
| Return on Equity | -240% |
| Return on Assets | -174.1% |
| Turnover Ratio | 12.2% |
| EBITA | $-7.7 |
Balance Sheet and Cash Flow Measures
| Total Assets | $4.4 |
| Total Liabilities | $1.2 |
| Operating Cash Flow | $-4.9 |
| Investing Cash Flow | $0 |
| Financing Cash Flow | $6.9 |
